MODERN Labeling Act of 2020

United States116th CongressHR-5668House of Representatives
Updated: Nov 18, 2020

Summary

Making Objective Drug Evidence Revisions for New Labeling Act of 2020 or the MODERN Labeling Act of 2020 This bill authorizes the Food and Drug Administration (FDA) to require updates to outdated labels for certain generic drugs if the updates will provide a public health benefit. Generally, the FDA may use this authority to update the label of a generic version of a brand-name drug that has been withdrawn from the market for reasons other than safety or effectiveness.

Bill texts

Available versions
View official text

3 versions available

Timeline

  1. On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5805-5806)

    House of Representatives

  2. Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5805-5806)

  3. Motion to reconsider laid on the table Agreed to without objection.

    House of Representatives

  4. Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Senate